MONOCYTE CHEMOATTRACTANT PROTEIN-1 LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE

Authors

DOI:

https://doi.org/10.21856/j-PEP.2021.4.08

Keywords:

coronary artery disease, type 2 diabetes mellitus, monocyte chemoattractant protein-1

Abstract

Background. Mechanisms of atherosclerotic cardiovascular diseases in patients with diabetes mellitus have not been fully clarified. Monocyte chemoattractant protein-1 (MCP-1) is a proinflammatory chemokine which plays a key role in the pathophysiology of both atherosclerosis and diabetes.

The aim of the study was to investigate MCP-1 levels in patients with coronary artery disease (CAD) with type 2 diabetes mellitus (T2DM) depending on previous history of myocardial infarction and percutaneous coronary intervention (PCI).

Materials and Methods. Serum MCP-1 levels were measured in 31 patients with stable CAD with T2DM, 26 non-DM patients with CAD, and 15 control group persons.

Results. MCP-1 level in patients with CAD with T2DM was higher than in the control group (p=0,0007) and non-DM patients with CAD (р=0,039). The elevation of MCP-1 level in non-DM patients with CAD was insignificant. There were no correlations of MCP-1 levels with glucometabolic and lipid indices in any groups. MCP-1 levels did not differ significantly in CAD patients with and without a history of previous myocardial infarction both in non-DM patients and in patients with T2DM. CAD patients with T2DM with a history of PCI more than 1 year previously have higher MCP-1 levels than CAD patients with T2DM without a history of PCI (p=0,038). In non-DM patients with CAD with the same history of PCI MCP-1 decreased compared to non-DM patients without previous PCI (p=0,030).

Conclusions. In patients with CAD with T2DM MCP-1 level increased in comparison with the controls and CAD patients without T2DM. CAD patients with T2DM with a history of PCI have highest MCP-1 level.

Author Biographies

Serhii A. S., GI «L.T. Malaya Therapy National Institute of the NAMS of Ukraine», Kharkiv, Ukraine

MD, PhD, DrMedSc, Head of Department of Ischemic Heart Disease and Metabolic Disorders, Government Institution “L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”

Mavrycheva N. R., G I “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”

MD, Junior Researcher, Department of Ischemic Heart Disease and Metabolic Disorders, Government Institution “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”

Chenchyk T. O., G I “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”,

PhD, Senior Researcher, Laboratory of Immuno-Biochemical and Molecular-Genetic Research, Government Institution “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine”

References

Bancks MP, Ning H, Allen NB, et al. Diabetes Care 2019;42(3): 457-465. https://doi.org/10.2337/dc18-1773.

Mak K-H,Vidal-Petiot E, Young R, et al. Eur J Prev Cardiol 2021; zwab011. https://doi.org/10.1093/eurjpc/zwab011.

Gholap NN, Achana FA, Davies MJ, et al. Diabetes Obes Metab 2017;19(3): 364-374. https://doi.org/10.1111/dom.12827.

Chichareon P, Modolo R, Kogame N, et al. Atherosclerosis 2020;295: 45-53. https://doi.org/10.1016/j.atherosclerosis.2020.01.002.

Eckel RH, Bornfeldt KE, Goldberg IJ. Cell Metab 2021;33(8): 1519-1545. https://doi.org/10.1016/j.cmet.2021.07.001.

Poznyak A, Grechko AV, Poggio P, et al. Int J Mol Sci 2020;21(5): 1835. https://doi.org/10.3390/ijms21051835.

Ministrini S, Carbone F, Montecucco F. Eur J Clin Invest 2021;51(5): e13467. https://doi.org/10.1111/eci.13467.

Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Int J Mol Sci 2020;21(17): 6275. https://doi.org/10.3390/ijms21176275.

La Sala L, Prattichizzo F, Ceriello A. Eur J Prev Cardiol 2019;26(2): 15-24. https://doi.org/10.1177/2047487319878373.

Bianconi V, Sahebkar A, Atkin SL, Pirro M. Curr Opin Hematol 2018;25(1): 44-51. https://doi.org/10.1097/MOH.0000000000000389.

Dommel S, Blüher M. Int J Mol Sci 2021;22(3): 1500. https://doi.org/10.3390/ijms22031500.

Pan X, Kaminga AC, Wen SW, Liu A. Front Immunol 2021;12: 622438. https://doi.org/10.3389/fimmu.2021.622438.

Schiopu A, Bengtsson E, Gonçalves I, et al. J Am Heart Assoc 2016;5(9): e002851. https://doi.org/10.1161/JAHA.115.002851.

Georgakis MK, de Lemos JA, Ayers C, et al. JAMA Cardiol 2021;6(5): 587-592. https://doi.org/10.1001/jamacardio.2020.5392.

Li J, Zhang Y, Guo X, et al. Pharmgenomics Pers Med 2021;14: 553-559. https://doi.org/10.2147/PGPM.S303362.

Blanco-Colio LM, Méndez-Barbero N, Pello Lázaro AM, et al. J Clin Med 2021;10(5): 1137. https://doi.org/10.3390/jcm10051137.

Georgakis MK, Malik R, Björkbacka H, et al. Circ Res 2019;125(8): 773-782. https://doi.org/10.1161/CIRCRESAHA.119.315380.

Ahmed SF, Shabayek MI, Abdel Ghany ME, et al. PLoS One 2018;13(12): e0208038. https://doi.org/10.1371/journal.pone.0208038.

Subirana I, Fitó M, Diaz O, et al. Sci Rep 2018;8(1): 3191. https://doi.org/10.1038/s41598-018-21482-y.

Macarie RD, Vadana M, Ciortan L, et al. J Cell Mol Med 2018;22(9): 4366-4376. https://doi.org/10.1111/jcmm.13728.

Jia S, Yang S, Du P, et al. Front Genet 2019;10: 1098. https://doi.org/10.3389/fgene.2019.01098.

Zhao X, Lan J, Yu X, et al. Front Cardiovasc Med 2021;8: 653467. https://doi.org/10.3389/fcvm.2021.653467.

Ravindran D, Galougahi KK, Tan JTM, et al. Cardiovasc Res 2020: cvaa072. https://doi.org/10.1093/cvr/cvaa072.

Downloads

Published

2021-12-03

How to Cite

Серік, С., Мавричева, Н., & Ченчик, Т. (2021). MONOCYTE CHEMOATTRACTANT PROTEIN-1 LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CORONARY ARTERY DISEASE . Problems of Endocrine Pathology, 78(4), 57-64. https://doi.org/10.21856/j-PEP.2021.4.08

Issue

Section

CLINICAL ENDOCRINOLOGY